Eli Lilly and Company

Q1 2024 Earnings Call

April 30, 2024

Safe Harbor Provision

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform.

For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP.

These materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions.

The company undertakes no duty to update forward-looking statements except as required by applicable law

Lilly

Agenda

Introduction and Key Events
Dave Ricks, Chair and Chief Executive Officer

Q1 2024 Financial Results
Anat Ashkenazi, Chief Financial Officer

R&D Update
Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer

Closing Remarks
Dave Ricks, Chair and Chief Executive Officer

Question & Answer Session

Strategic Deliverables

PROGRESS SINCE THE LAST EARNINGS CALL

Invest in Current Portfolio

- **Gross Margin**: Non-GAAP gross margin of 82.5% in Q1
- **SG&A**: 12% increase in Q1 primarily driven by promotional efforts supporting launches as well as increased compensation and benefit costs

Invest in Future Innovation

- **R&D**: 27% increase in Q1 driven by higher development expenses for late-stage assets and additional investments in early-stage research
- **Business Development**: Announced an agreement to acquire an injectable medicine manufacturing facility with production targeted to begin at the end of 2025
- **Capex:** Progressed manufacturing expansion agenda with groundbreaking at our previously announced $2.5 billion parenteral manufacturing site in Germany

Deliver Revenue Growth

- Revenue grew 26% in Q1 driven by Mounjaro®, Zepbound®, Verzenio®, and Jardiance®[1]
- New Product[2] revenue grew by $1.79 billion to $2.39 billion in Q1

Speed Life-Changing Medicines

- Announced positive topline results for tirzepatide in moderate-to-severe obstructive sleep apnea and obesity
- Received approval of the multi-dose KwikPen® delivery device for Mounjaro in the EU
- Submitted mirikizumab in the U.S. and EU for moderately to severely active Crohn's disease
- Resubmitted lebrikizumab in the U.S. for moderate-to-severe atopic dermatitis
- Initiated Phase 3 program for lepodisiran in reducing cardiovascular risk

Return Capital to Shareholders:

Distributed over $1 billion via **dividends** in Q1

[1] Jardiance is part of the Boehringer Ingelheim and Lilly Alliance, and Boehringer Ingelheim holds the marketing authorization for Jardiance

[2] Refer to slide 8 for a list of New Products

Key Events Since Last Earnings Call

Regulatory

- Submitted **mirikizumab** in the U.S. and EU for moderately to severely active Crohn's disease
- Resubmitted **lebrikizumab** in the U.S. for moderate-to-severe atopic dermatitis
- Announced that the U.S. Food and Drug Administration plans to convene an Advisory Committee meeting to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial of **donanemab** in early symptomatic Alzheimer's disease, which we expect to occur in mid-2024
- Received approval of the multi-dose KwikPen® delivery device for **Mounjaro** in the EU with expected launch in the first EU market in the coming weeks

Clinical

- Announced positive topline results of the SURMOUNT-OSA Phase 3 clinical trials showing **tirzepatide** achieved a mean AHI reduction of up to 63% in adults with moderate-to-severe OSA and obesity compared to placebo
- Announced results from Phase 3 EMPACT-MI trial of **Jardiance**[1] on risk of heart failure hospitalization and death in adults following a heart attack

Clinical (Cont)

- Presented results from a study of **lebrikizumab** in people with skin of color and atopic dermatitis
- Terminated the Phase 3 CYCLONE-3 trial evaluating **Verzenio** in metastatic hormone-sensitive prostate cancer for futility following an interim analysis
- Presented preclinical data for agents in our **oncology** pipeline targeting Nectin-4, KRAS G12D, and BRM (SMARCA2)

Other

- Announced an agreement to acquire **an injectable medicine manufacturing facility** from Nexus Pharmaceuticals in Pleasant Prairie, Wisconsin. This state-of-the-art facility is FDA approved, and we are targeting to initiate production at the end of 2025
- Initiated groundbreaking on our previously-announced $2.5 billion **parenteral manufacturing** site in Alzey, Germany

AHI = Apnea-hypopnea index; OSA = obstructive sleep apnea

[1] Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information; Certain Line Items (Unaudited)

Dollars in millions; except per share data

	Q1 2024			
	GAAP Reported	Adjustments	Non-GAAP Adjusted	YoY Non-GAAP Adjusted Change
TOTAL REVENUE	**$8,768**	$ –	**$8,768**	26%
GROSS MARGIN	**80.9%**	1.6pp	**82.5%**	4.1pp
TOTAL OPERATING EXPENSE	**$4,586**	$ –	**$4,586**	19%
OPERATING INCOME	**$2,509**	$139	**$2,648**	63%
OPERATING MARGIN	**28.6%**	1.6pp	**30.2%**	6.9pp
OTHER INCOME (EXPENSE)	**$27**	$(23)	**$4**	(94)%
EFFECTIVE TAX RATE	**11.6%**	0.3pp	**11.9%**	(0.9)pp
NET INCOME	**$2,243**	$92	**$2,335**	60%
EPS	**$2.48**	$0.10	**$2.58**	59%
Acquired IPR&D Charges per share*	**$0.10**	$ –	**$0.10**	$–

*Acquired IPR&D (in-process research and development) of $111 million (pre-tax)
Numbers may not add due to rounding; see slide 23 for a complete list of adjustments

Price/Rate/Volume Effect on Revenue

Dollars in millions

	Q1 2024					
	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$5,694	16%	–	12%	28%	28%
EUROPE	1,441	1%	3%	28%	32%	29%
JAPAN	364	(5)%	(8)%	7%	(6)%	2%
CHINA	376	(4)%	(3)%	8%	1%	4%
REST OF WORLD	893	(0)%	1%	32%	33%	31%
TOTAL REVENUE	$8,768	10%	(0)%	16%	26%	26%

Numbers may not add due to rounding

CER = price change + volume change

Q1 2024 Update on Select Products



New Products: Ebglyss®, Jaypirca®, Mounjaro, Omvoh®, and Zepbound
Growth Products: Cyramza®, Emgality®, Jardiance[1], Olumiant®, Retevmo®, Taltz®, Trulicity®, Tyvyt®, and Verzenio

NEW PRODUCTS

MOUNJARO

- U.S. T2D injectable incretins TRx SOM over 24% and NBRx SOM nearly 30% at end of Q1 2024

ZEPBOUND

- U.S. branded anti-obesity rolling 4-week TRx SOM nearly 40% and rolling 4-week NBRx SOM nearly 57% at end of Q1 2024

JAYPIRCA

- Q1 2024 sales increased to $50 million, representing an acceleration in sequential quarterly growth following the Q4 2023 approval in CLL

OMVOH

- Japan and EU approval in H1 2023; U.S. approval and launch in Q4 2023

GROWTH PRODUCTS

JARDIANCE[1]

- SGLT2 market leader in several key countries with U.S. TRx SOM over 63% at end of Q1 2024
- U.S. TRx grew over 24% vs. Q1 2023

TALTZ

- U.S. immunology TRx SOM of nearly 6% at end of Q1 2024
- U.S. TRx grew 8% vs. Q1 2023

TRULICITY

- U.S. T2D injectable incretins TRx SOM of 19% at end of Q1 2024

VERZENIO

- U.S. TRx grew over 32% vs. Q1 2023
- Strong uptake in adjuvant breast cancer indication

[1] Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.

Zepbound U.S. Launch Progress

- **Exceptionally strong launch** progress since U.S. FDA approval on November 8, 2023
- We are **rapidly building access** in the U.S. and, as of April 1, we have approximately 67% access in commercial
- Continued focus on **broadening formulary access** and through **employer opt-ins**; early progress is encouraging

Capital Allocation

$ in Billions



* After tax

** Includes development milestones, closed acquisitions and cash outflows associated with equity investments

2024 Guidance

	Prior	Updated	Comments
REVENUE	$40.4 – $41.6 billion	$42.4 – $43.6 billion	New midpoint represents ~26% total growth and ~35% growth excluding impact of global divestiture transactions
GROSS MARGIN – OPEX [1] **REVENUE**			
(GAAP)	30% – 32%	32% – 34%	Reflects increase in revenue guidance
(NON-GAAP)	31% – 33%	33% – 35%	
OTHER INCOME/(EXPENSE)			
(GAAP)	$(500) – $(400) million	Unchanged	
(NON-GAAP)	$(500) – $(400) million		
TAX RATE	Approx. 14%	Unchanged	
EARNINGS PER SHARE[2]			
(GAAP)	$11.80 – $12.30	$13.05 – $13.55	Reflects increase in revenue guidance and Q1 acquired IPR&D charges of $0.10 per share
(NON-GAAP)	$12.20 – $12.70	$13.50 – $14.00	

[1] OPEX is defined as the sum of research and development expenses and marketing, selling and administrative expenses
[2] 2024 assumes shares outstanding of approximately 903 million. Earnings per share (non-GAAP) reflects $0.48 adjustment for amortization of intangible assets
IPR&D = in-process research and development

FX assumptions of 1.08 (Euro), 151 (Yen) and 7.10 (Renminbi)

SURMOUNT-OSA Phase 3 Studies

Master Protocol to evaluate tirzepatide in two studies in distinct populations with moderate-to-severe OSA and obesity



- In Study 1, tirzepatide was evaluated in participants not on PAP therapy
- In Study 2, tirzepatide was evaluated in participants who had used PAP therapy for at least 3 months at screening and planned to continue PAP therapy during the study
- Separate studies allowed us to assess the effect of tirzepatide irrespective of PAP therapy use
- The studies enrolled 469 participants and evaluated the maximum tolerated dose of 10 or 15mg tirzepatide versus placebo for 52 weeks

OSA = obstructive sleep apnea; PAP = Positive Airway Pressure; MTD = maximum tolerated dose; QW = weekly

SURMOUNT-OSA Study 1 – Not on PAP Therapy



- Tirzepatide led to a mean AHI reduction of 27.4 events per hour, compared to 4.8 for placebo
- Tirzepatide led to a mean AHI reduction of 55.0% from baseline, compared to 5.0% for placebo
- Participants in the tirzepatide arm had a mean body weight reduction of 18.1%* from baseline, compared to 1.3% for placebo
- The overall safety profile of tirzepatide in Study 1 was similar to previously reported SURMOUNT and SURPASS trials

AHI = apnea-hypopnea index; ΔAHI = change from baseline in AHI (events per hour); PAP = Positive Airway Pressure
Note: Results for efficacy estimand which represents efficacy prior to discontinuation of study drug
Tirzepatide vs. placebo: *p<0.001

SURMOUNT-OSA Study 2 – On PAP Therapy



- Tirzepatide led to a mean AHI reduction of 30.4 events per hour, compared to 6.0 for placebo
- Tirzepatide led to a mean AHI reduction of 62.8% from baseline, compared to 6.4% for placebo
- Participants in the tirzepatide arm had a mean body weight reduction of 20.1%* from baseline, compared to 2.3% for placebo
- The overall safety profile of tirzepatide in Study 2 was similar to previously reported SURMOUNT and SURPASS trials

AHI = apnea-hypopnea index; ΔAHI = change from baseline in AHI (events per hour); PAP = Positive Airway Pressure
Note: Results for efficacy estimand which represents efficacy prior to discontinuation of study drug
Tirzepatide vs. placebo: *p<0.001

Lilly Select NME and NILEX Pipeline

April 26, 2024

LEGEND

- NME
- NILEX
- * *Commercial Collaboration*
- *MOVEMENT SINCE February 5, 2023*
- ADDITION or MILESTONE ACHIEVED
- REMOVAL
- ◈ Phase 3 in China with Innovent for T2DM and Obesity

PHASE 1

- NECTIN-4 ADC 1 — Cancer
- SARM1 INHIBITOR — Neurodegeneration
- SCAP siRNA — NASH
- 225Ac-PSMA-62 PNT2001 — Prostate Cancer
- NRG4 AGONIST — Heart Failure
- PI3K SELECTIVE — Cancer
- PNPLA3 siRNA — NASH
- NOT DISCLOSED — Diabetes
- NOT DISCLOSED — Neurodegeneration
- NOT DISCLOSED — Pain
- ITACONATE MIMETIC — Immunology
- LA-ANP — Heart Failure
- NISOTIROSTIDE — Diabetes
- GIPR AGONIST LA II — Diabetes
- GITR ANTAGONIST — Immunology
- GS INSULIN RECEPTOR AGONIST — Diabetes
- DC-853 — Immunology
- FGFR3 SELECTIVE — Cancer
- GIPR AGONIST LA — Diabetes
- APOC3 siRNA — CVD
- AT2R ANTAGONIST — Pain
- DACRA QW II — Obesity

PHASE 2

- TIRZEPATIDE — Higher Doses
- TIRZEPATIDE — MASH
- ELORALINTIDE (AMYLIN AGONIST LA) — Obesity
- GBA1 GENE THERAPY — Gaucher Disease Type 1
- VOLENRELAXIN — Heart Failure
- CD19 ANTIBODY — Multiple Sclerosis
- SSTR4 AGONIST — Pain
- UCENPRUBART — Atopic Dermatitis
- PERESOLIMAB — Rheumatoid Arthritis
- SOLBINSIRAN — CVD
- OTOF GENE THERAPY — Hearing Loss
- P2X7 INHIBITOR — Pain
- OCADUSERTIB — Rheumatoid Arthritis
- OLOMORASIB — KRAS G12C-mutant NSCLC
- MUVALAPLIN — CVD
- O-GLCNACASE INH — Alzheimer's Disease
- MAZDUTIDE ◈ — Obesity
- MEVIDALEN — Symptomatic LBD
- GRN GENE THERAPY — Frontotemporal Dementia
- KV1.3 ANTAGONIST — Psoriasis
- ELTREKIBART — Hidradenitis Suppurativa
- GBA1 GENE THERAPY — Parkinson's Disease
- BIMAGRUMAB — Obesity
- DC-806 — Psoriasis

PHASE 3

- TIRZEPATIDE — Obstructive Sleep Apnea
- RETATRUTIDE — Diabetes
- TIRZEPATIDE — Heart Failure pEF
- TIRZEPATIDE — MMO
- SELPERCATINIB — Adjuvant RET+ NSCLC
- TIRZEPATIDE — CV Outcomes
- PIRTOBRUTINIB — R/R CLL Monotherapy
- PIRTOBRUTINIB — R/R MCL Monotherapy
- PIRTOBRUTINIB — 1L CLL Monotherapy
- PIRTOBRUTINIB — R/R CLL Combination
- IMLUNESTRANT — Adjuvant Breast Cancer
- ORFORGLIPRON — Diabetes
- ABEMACICLIB — MBC Sequencing
- DONANEMAB — Preclinical Alzheimer's Disease
- RETATRUTIDE — Obesity, OA, OSA
- LEPODISIRAN — ASCVD
- ORFORGLIPRON — Obesity
- REMTERNETUG — Alzheimer's Disease
- IMLUNESTRANT — ER+ HER2- mBC
- INSULIN EFSITORA ALFA — Diabetes

REG REVIEW

- MIRIKIZUMAB — Crohn's Disease
- DONANEMAB — Alzheimer's Disease

APPROVED

REMOVED

- NOT DISCLOSED — Immunology
- GBA1 GENE THERAPY — Gaucher Disease Type 2
- ABEMACICLIB — Hormone Sensitive Prostate Cancer
- EMPAGLIFLOZIN* — Post MI

Potential Key Events 2024

New since last update

Phase 3 Initiations

- Retatrutide for type 2 diabetes
- Retatrutide for cardiovascular outcomes in chronic weight management
- Lepodisiran [Lp(a) SiRNA] for cardiovascular disease
- Olomorasib [KRAS G12C] for first-line non-small cell lung cancer
- Remternetug for early Alzheimer's disease [efficacy trials]
- Lebrikizumab for chronic rhinosinusitis with nasal polyposis
- Lebrikizumab for allergic rhinitis due to perennial allergens

Phase 3 Data Disclosures

- Tirzepatide for obstructive sleep apnea [SURMOUNT-OSA]
- Tirzepatide for HFpEF [SUMMIT]
- Tirzepatide H2H study vs. semaglutide [SURMOUNT-5] [1]
- Insulin efsitora alfa for diabetes [QWINT-1 / 2 / 3 / 4 / 5]
- Abemaciclib for metastatic CRPC[2] [CYCLONE-2]
- Imlunestrant for metastatic breast cancer [EMBER-3]

Regulatory Submissions

- Mirikizumab for Crohn's disease [US / EU /J]
- Tirzepatide for obstructive sleep apnea [US/ EU]
- Tirzepatide for HFpEF [US]
- Tirzepatide for chronic weight management [JP]
- Imlunestrant for metastatic breast cancer [US/EU/J]
- Pirtobrutinib for CLL prior BTKi + BCL2 [EU/J]

Regulatory Actions

- Lebrikizumab for atopic dermatitis [US/J]
- Donanemab for early Alzheimer's disease[3] [US/EU/J]
- Empagliflozin[4] for chronic kidney disease [J]
- Pirtobrutinib for MCL prior BTKi [J]

[1] Classified as a Phase 3B/4 study
[2] CRPC = castrate-resistant prostate cancer
[3] Under the traditional approval pathway
[4] Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.

Q1 2024 Summary

- **Revenue grew 26%** driven by Mounjaro, Zepbound, Verzenio, and Jardiance[1]
- Continued to **speed life-changing medicines** to patients with:
  - Positive topline results of tirzepatide in moderate-to-severe obstructive sleep apnea and obesity
  - Approval of the multi-dose KwikPen® delivery device for Mounjaro in the EU
  - Submission of mirikizumab in the U.S. and EU for moderately to severely active Crohn's disease
  - Resubmission of lebrikizumab in the U.S. for moderate-to-severe atopic dermatitis
  - Initiation of Phase 3 program for lepodisiran in reducing cardiovascular risk
- Q1 **investment growth** largely driven by recent and upcoming launches, internal and external pipeline development, and progress on a **comprehensive manufacturing expansion** agenda
- Returned over $1 billion to shareholders via the **dividend**



[1] Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.

Supplemental Slides

2024 Income Statement – Reported

Dollars in millions; except per share data

	Q1 2024	Change
TOTAL REVENUE	$8,768	26%
GROSS MARGIN	80.9%	4.3pp
TOTAL OPERATING EXPENSE*	$4,586	19%
OPERATING INCOME	$2,509	68%
OPERATING MARGIN	28.6%	7.1pp
OTHER INCOME (EXPENSE)	$27	(24)%
EFFECTIVE TAX RATE	11.6%	(0.5)pp
NET INCOME	$2,243	67%
EARNINGS PER SHARE	$2.48	66%

* Includes research and development expense; marketing, selling and administrative expense; acquired in-process research and development charges; and asset impairment, restructuring and other special charges (as applicable)

(Gross Margin – OPEX[1]) / Revenue Ratio



Non-GAAP (Gross Margin – OPEX[1]) / Revenue Ratio:	**24.8%**	**28.3%**	**37.4%**	**34.3%**	**31.5%**
GAAP (Gross Margin – OPEX[1]) / Revenue Ratio:	**23.0%**	**26.7%**	**36.1%**	**32.9%**	**29.9%**

[1] OPEX is defined as the sum of research and development expenses and marketing, selling and administrative expenses
The line in the graph is the non-GAAP moving annual total (i.e. trailing 4 quarters) while the rows of numbers are from specific quarters
Note: The Non-GAAP ratios for the periods presented exclude the amortization of intangible assets. The applicable impact of amortization of intangible assets can be found in the reconciliation tables of the respective quarterly earnings releases.

Effect of FX on 2024 Results

Year-on-Year Change

	Q1 2024	
REPORTED	With FX	w/o FX
TOTAL REVENUE	26%	26%
COST OF SALES	3%	2%
GROSS MARGIN	33%	33%
OPERATING EXPENSE	19%	19%
OPERATING INCOME	68%	69%
EARNINGS PER SHARE	66%	68%

NON-GAAP	With FX	w/o FX
TOTAL REVENUE	26%	26%
COST OF SALES	2%	2%
GROSS MARGIN	33%	33%
OPERATING EXPENSE	19%	19%
OPERATING INCOME	63%	64%
EARNINGS PER SHARE	59%	60%

Presentation includes GAAP and non-GAAP figures excluding impact of foreign exchange rates. Current period figures recalculated by keeping constant the exchange rates from the base period.

EPS Reconciliation

	Q1 2024	Q1 2023	% Change
EARNINGS PER SHARE (REPORTED)	$2.48	$1.49	66%
AMORTIZATION OF INTANGIBLE ASSETS	0.12	0.11	9%
NET (GAINS) LOSSES ON INVESTMENTS IN EQUITY SECURITIES	(0.02)	0.02	NM
EARNINGS PER SHARE (NON-GAAP)	$2.58	$1.62	59%
Acquired IPR&D	$0.10	$0.10	–

Numbers may not add due to rounding; see slide 23 for more details on these adjustments; NM = not meaningful

Q1 2024 Income Statement Notes

Q1 2024 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $139.1 million (pre-tax), or $0.12 per share (after-tax); and
- net gains on investments in equity securities totaling ($23.4) million (pre-tax), or ($0.02) per share (after-tax).

Q1 2023 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $125.8 million (pre-tax), or $0.11 per share (after-tax); and
- net losses on investments in equity securities totaling $22.6 million (pre-tax), or $0.02 per share (after-tax).

Comparative EPS Summary 2023/2024

Dollars

	1Q23	2Q23	3Q23	4Q23	2023	1Q24	2Q24	3Q24	4Q24	2024
Reported	1.49	1.95	(0.06)	2.42	5.80	2.48				
Non-GAAP	1.62	2.11	0.10	2.49	6.32	2.58				

Numbers may not add due to rounding

For a complete reconciliation to reported earnings, see slide 22 and our earnings press release dated April 30, 2024

Q1 2024 Mounjaro Sales Increased $1.2B

$ in Millions

U.S. sales were $1.5 billion
International sales were $286 million



U.S. TRx SOM and Market Volume



Note: Lilly T2D Injectable Incretins consist of Mounjaro & Trulicity 13 Wk RA TRx SOM

Source: IQVIA NPA TRx 3MMA, weekly data March 29, 2024; RA = rolling average
TRx data is representative of the injectable incretin market

Q1 2024 Trulicity Sales Decreased 26%

$ in Millions

U.S. sales decreased 30%
International sales decreased 13%



U.S. TRx SOM and Market Volume



Note: Lilly T2D Injectable Incretins consist of Mounjaro & Trulicity 13 Wk RA TRx SOM

Source: IQVIA NPA TRx 3MMA, weekly data March 29, 2024; RA = rolling average
TRx data is representative of the injectable incretin market

Q1 2024 Verzenio Sales Increased 40%

$ in Millions

U.S. sales increased 38%
International sales increased 42%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data March 29, 2024; RA = rolling average

Q1 2024 Jardiance Sales Increased 19%

$ in Millions

U.S. sales increased 12%
International sales increased 28%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data March 29, 2024; RA = rolling average

[1] Jardiance includes Glyxambi and Synjardy. Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.

Q1 2024 Taltz Sales Increased 15%

$ in Millions

U.S. sales increased 11%
International sales increased 20%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data March 29, 2024; RA = rolling average
TRx data is representative of the full molecule market

Q1 2024 Humalog Sales Increased 17%

$ in Millions

U.S. sales increased 25%
International sales increased 6%



U.S. TRx SOM



Source: IQVIA NPA TRx 3MMA, weekly data March 29, 2024; RA = rolling average

Select Trials – Insulin Efsitora Alfa

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05362058	Diabetes	A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-2)	3	928	Change from Baseline in Hemoglobin A1c (HbA1c)	Apr 2024	Apr 2024
NCT05275400	Type 2 Diabetes	A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)	3	986	Change from Baseline in Hemoglobin A1c (HbA1c)	May 2024	May 2024
NCT05662332	Type 2 Diabetes	A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)	3	796	Change from Baseline in Hemoglobin A1c (HbA1c)	Jul 2024	Jul 2024
NCT05463744	Type 1 Diabetes	A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy (QWINT-5)	3	692	Change from Baseline in Hemoglobin A1c (HbA1c)	May 2024	May 2024

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 18, 2024

Select Trials – Donanemab

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04437511	Alzheimer Disease	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	3	1736	Change from Baseline on the integrated Alzheimer's Disease Rating Scale (iADRS)	Apr 2023	Aug 2025
NCT05738486	Alzheimer Disease	A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)	3	800	Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)	Jun 2024	May 2025
NCT05508789	Alzheimer Disease	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)	3	1500	Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)	Apr 2027	Apr 2027
NCT05026866	Alzheimer Disease	A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)	3	2600	Time to clinical progression as measured by Clinical Dementia Rating - Global Score (CDR-GS)	Nov 2027	Nov 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2024

Select Trials – Imlunestrant

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04975308	Breast Neoplasms	A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)	3	860	Progression Free Survival (PFS) in the Intent-to-Treat (IIT) Population	Apr 2024	Aug 2027
NCT05514054	Breast Neoplasms	A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)	3	6000	Invasive Disease-Free Survival (IDFS)	Oct 2027	Mar 2032

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2024

Select Trials – Lebrikizumab

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05369403	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab (ADapt)	3	120	Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) >75% Reduction in EASI Score	Jan 2024	Dec 2024
NCT05372419	Atopic Dermatitis	A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color (ADmirable)	3	80	Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) (≥75% reduction from baseline in EASI)	May 2024	Dec 2024
NCT05559359	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)	3	300	Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) ≥75% Reduction from Baseline in EASI Score	Jul 2024	Jun 2025
NCT04392154	Atopic Dermatitis	Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)	3	1188	Percentage of Participants Discontinued from Study Treatment due to Adverse Events through the Last Treatment Visit	Sep 2024	Apr 2025
NCT05735483	Atopic Dermatitis	A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)	3	250	Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)	Jun 2026	Jun 2026

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2024

Select Trials – Lepodisiran

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05565742	Lipoprotein Disorder	A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] (ALPACA)	2	216	Percent Change from Baseline in Time Averaged Lipoprotein(a) [Lp(a)]	Oct 2023	Oct 2024
NCT06292013	Atherosclerotic Cardiovascular Disease (ASCVD)[1]	A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	3	12500	Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint	Mar 2029	Mar 2029

[1] Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD)

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 8, 2024

Select Trials – Mirikizumab

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04232553	Crohn's Disease	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)	3	778	Percentage of Participants Achieving Endoscopic Response	Jan 2025	Dec 2026
NCT03518086	Ulcerative Colitis	An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-1)	3	1281	Percentage of Participants With Clinical Remission at Week 12	Jan 2021	May 2024
NCT03524092	Ulcerative Colitis	A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-2)	3	1177	Percentage of Participants in Clinical Remission at Week 40	Nov 2021	Dec 2024
NCT03519945	Ulcerative Colitis	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-3)	3	1063	Percentage of Participants in Clinical Remission	Jul 2026	Dec 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 17, 2024

Select Trials – Orforglipron

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05971940	Type 2 Diabetes	A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise (ACHIEVE-1)	3	520	Change from Baseline in Hemoglobin A1c (HbA1c)	Apr 2025	Apr 2025
NCT05803421	Type 2 Diabetes	A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)	3	2620	Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]	Apr 2025	Dec 2025
NCT06109311	Type 2 Diabetes	A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)	3	520	Change from Baseline in Hemoglobin A1c (HbA1c) Compared to Placebo	Jun 2025	Jun 2025
NCT06010004	Type 2 Diabetes	A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes (ACHIEVE-J)	3	399	Number of Participants with Treatment Emergent Adverse Events (TEAEs)	Jun 2025	Jun 2025
NCT06045221	Type 2 Diabetes	A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (ACHIEVE-3)	3	1576	Change from Baseline in Hemoglobin A1c (HbA1c)	Jul 2025	Jul 2025
NCT06192108	Type 2 Diabetes	A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)	3	888	Change from Baseline in Hemoglobin A1c (HbA1c)	Oct 2025	Oct 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2024

Select Trials – Orforglipron (Cont.)

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05872620	Obesity	A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)	3	1500	Mean Percent Change from Baseline in Body Weight	Jun 2025	Jun 2025
NCT05931380	Obesity	A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease (ATTAIN-J)	3	236	Mean Percent Change in Body Weight	Jun 2025	Jul 2025
NCT05869903	Obesity	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)	3	3000	Mean Percent Change from Baseline in Body Weight	Sep 2025	Sep 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2024

Select Trials – Pirtobrutinib

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04666038	Chronic Lymphocytic Leukemia	Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)	3	250	To evaluate progression-free survival (PFS) of LOXO-305 monotherapy (Arm A) compared to investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) (Arm B)	Nov 2023	May 2027
NCT05023980	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)	3	250	To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)	Jan 2025	May 2026
NCT04965493	Chronic Lymphocytic Leukemia	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)	3	600	To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)	Oct 2025	Jan 2027
NCT05254743	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-314)	3	650	Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR)	Mar 2028	Mar 2029
NCT04662255	Lymphoma, Mantle-Cell	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN MCL-321)	3	500	To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)	Apr 2025	Apr 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 5, 2024

Select Trials – Remternetug

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05463731	Alzheimer Disease	A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)	3	600	Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo	Oct 2025	Oct 2026

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 16, 2024

Select Trials – Retatrutide

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05936151	Chronic Kidney Disease	A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	2	120	Change from Baseline in Glomerular Filtration Rate (GFR)	Nov 2025	Nov 2025
NCT05882045	Obesity	A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)	3	1800	Percent Change from Baseline in Body Weight	Jan 2026	Feb 2026
NCT05931367	Obesity	A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4)	3	405	Percent Change from Baseline in Body Weight and Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score	Feb 2026	Mar 2026
NCT05929066	Obesity	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)	3	2100	Percent Change From Baseline in Body Weight	Apr 2026	May 2026
NCT05929079	Obesity	A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)	3	1000	Percent Change from Baseline in Body Weight	May 2026	May 2026

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2024

Select Trials – Retatrutide (Cont.)

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06354660	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)	3	480	Change from Baseline in Hemoglobin A1c (HbA1c)	Jun 2026	Jul 2026
NCT06297603	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)	3	320	Change from Baseline in Hemoglobin A1c (HbA1c)	Sep 2026	Oct 2026
NCT06260722	Type 2 Diabetes	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	3	1250	Change from Baseline in Hemoglobin A1c (HbA1c)	Dec 2026	Mar 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2024

Select Trials – Retevmo

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04211337	Medullary Thyroid Cancer	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	3	291	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)	May 2023	Feb 2026
NCT04194944	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)	3	261	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with Pembrolizumab)	May 2023	Jun 2026
NCT03157128	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	1|2	875	Phase 1: MTD; Phase 2: ORR	Feb 2025	Feb 2026
NCT04819100	Carcinoma, Non-Small-Cell Lung	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)	3	170	Event-Free Survival (EFS)	May 2027	Aug 2032

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, March 26, 2024

Select Trials – Tirzepatide

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04184622	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)	3	2539	Percent Change from Baseline in Body Weight	Apr 2022	Jul 2024
NCT05822830	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5)	3	700	Percent Change from Baseline in Body Weight	Nov 2024	Nov 2024
NCT06047548	Obesity	A Study of Tirzepatide (LY3298176) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)	3	400	Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period	May 2026	May 2026
NCT06075667	Obesity	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS)	3	150	Percent Change from Baseline in Body Mass Index (BMI)	Oct 2026	Oct 2026
NCT05556512	Obesity	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)	3	15374	Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)	Oct 2027	Oct 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2024

Select Trials – Tirzepatide (Cont.)

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04255433	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)	3	13299	Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3)	Jun 2025	Jun 2025
NCT05260021	Type 2 Diabetes	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (SURPASS-PEDS)	3	99	Change From Baseline in Hemoglobin A1c (HbA1c)	Aug 2024	Feb 2025
NCT06037252	Type 2 Diabetes	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	2	350	Percent Change From Baseline in Body Weight	Dec 2024	Sep 2025
NCT04847557	HFpEF	A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)	3	731	Change from Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) [Time Frame: Baseline, Week 52]	Jun 2024	Jul 2024
NCT05536804	CKD	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD)	2	140	Change from Baseline in Kidney Oxygenation in Participants With or Without T2D [Time Frame: Baseline, Week 52]; Blood oxygenation-level dependent magnetic resonance imaging (BOLD MRI)	Jan 2026	Feb 2026

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2024

Select Trials – Verzenio

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03155997[1]	Breast Cancer	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)	3	5637	Invasive Disease-Free Survival (IDFS)	Mar 2020	May 2029
NCT05169567	Breast Neoplasm	Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMonarch)	3	368	Progression-Free Survival (PFS)	Feb 2024	Feb 2026

[1] Also lists NSABP Foundation Inc

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2024

Select Trials – Early Phase Diabetes and Obesity

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Solbinsiran	NCT05256654	Dyslipidemias	A Study of LY3561774 in Participants With Mixed Dyslipidemia (PROLONG-ANG3)	2	175	Percent Change from Baseline for Apolipoprotein B (ApoB)	Mar 2024	Jun 2024
Bimagrumab	NCT05616013	Obesity	Safety and Efficacy of Bimagrumab and Semaglutide in Adults who are Overweight or Obese	2	507	Change from baseline in body weight at 48 weeks	May 2024	Jun 2025
Mazdutide	NCT06124807	Obesity	A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight	2	165	Percent Change from Baseline in Body Weight	Nov 2024	May 2025
Eloralintide (Amylin Agonist LA)	NCT06230523	Obesity	A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight	2	225	Percent Change from Baseline in Body Weight	Jun 2025	Sep 2025
Volenrelaxin	NCT05592275	Heart Failure	A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)	2	432	Change from Baseline in Left Atrial Reservoir Strain (LARS)	Nov 2025	Jan 2026

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 18, 2024

Select Trials – Early Phase Diabetes and Obesity (Cont.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Muvalaplin	NCT06342596	Healthy	A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants	1	16	Part 1: Urinary Excretion of LY3473329 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered	Apr 2024	Apr 2024
DACRA QW II	NCT05380323	Obesity	A Study of LY3541105 in Healthy and Overweight Participants	1	205	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Aug 2024	Aug 2024
GS Insulin Receptor Agonist	NCT06132126	Healthy	A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus	1	88	Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Aug 2024	Aug 2024
GS Insulin Receptor Agonist	NCT06280703	Healthy	A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)	1	70	Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Feb 2025	Feb 2025
LA-ANP	NCT06148272	Healthy	A Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension	1	188	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Oct 2024	Oct 2024

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 18, 2024

Select Trials – Early Phase Diabetes and Obesity (Cont.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NRG4 Agonist	NCT04840914	HFrEF	A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction	1	50	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	May 2024	Jul 2024
PNPLA3 siRNA	NCT05395481	Non-Alcoholic Fatty Liver Disease	A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease	1	176	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Nov 2024	Nov 2024
SCAP siRNA	NCT06007651	Dyslipidemias	A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)	1	112	Part A: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Apr 2025	Apr 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 18, 2024

Select Trials – Early Phase Immunology

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Peresolimab	NCT05516758	Rheumatoid Arthritis	A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (RESOLUTION-1)	2	491	Percentage of Participants Achieving American College of Rheumatology (ACR)20	Nov 2023	Jan 2025
DC-806	NCT05896527	Plaque Psoriasis	A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis (ILLUMINATE)	2	229	Proportion of participants achieving a 75% reduction in Psoriasis Area of Severity Index score (PASI-75)	Feb 2024	Mar 2024
Ucenprubart	NCT05911841	Atopic Dermatitis	A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis	2	260	Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75	Sep 2024	May 2025
KV1.3 Antagonist	NCT06176768	Plaque Psoriasis	A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis	2	75	Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI 75)	Apr 2025	Jul 2025
Eltrekibart	NCT06046729	Hidradenitis Suppurativa	A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	2	350	Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)	Aug 2025	Jul 2026
Ocadusertib[1]	NCT05848258	Rheumatoid Arthritis	An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis	2	380	Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)	Feb 2026	Jul 2026

[1] Also lists Rigel Pharmaceuticals

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 16, 2024

Select Trials – Early Phase Immunology (Cont.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
CD19 Antibody	NCT06220669	Multiple Sclerosis	A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis	2	200	Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions	Aug 2027	Aug 2028
DC-853	NCT06311656	Healthy	A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants	1	30	Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs)	May 2024	May 2024
Itaconate Mimetic	NCT06153355	Healthy	A First-In-Human Study of LY3839840 in Healthy Participants	1	112	Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Jun 2024	Jun 2024

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 16, 2024

Select Trials – Early Phase Neurodegeneration

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
O-GlcNAcase Inh.	NCT05063539	Alzheimer Disease	A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease	2	330	Change from Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS)	Jul 2024	Aug 2024
SARM1 CNS Inhibitor	NCT05492201	Healthy	A Study of LY3873862 in Healthy Participants	1	90	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Dec 2024	Dec 2024

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 18, 2024

Select Trials – Early Phase Neurodegeneration (Cont.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
OTOF Gene Therapy	NCT05821959	Sensorineural Hearing Loss, Bilateral	Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss	1|2	14	Frequency of Adverse Events (AEs)	Oct 2028	Oct 2028
GRN Gene Therapy	NCT04408625	Frontotemporal Dementia	Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PROCLAIM)	1|2	23	Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation	Aug 2029	Aug 2029
GBA1 Gene Therapy	NCT04127578	Parkinson Disease	Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	1|2	20	Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Jun 2029	Jun 2029
GBA1 Gene Therapy	NCT05487599	Gaucher Disease	A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)	1|2	15	Incidence and severity of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Oct 2030	Oct 2030

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 18, 2024

Select Trials – Early Phase Oncology

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Olomorasib	NCT06119581	Carcinoma, Non-Small-Cell Lung	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)	3	1016	PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR)	Oct 2026	Oct 2029
Olomorasib[1]	NCT04956640	Carcinoma, Non-Small-Cell Lung	Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	1|2	450	Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy	Sep 2025	Sep 2025
PI3K Selective	NCT05307705	Breast Cancer	A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01)	1	400	Phase 1a: To determine the MTD/RP2D of LOXO-783: Number of patients with dose-limiting toxicities (DLTs)	May 2025	May 2025
FGFR3 Selective	NCT05614739	Urinary Bladder Neoplasms	A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3	1	180	Phase 1a: To determine the recommended phase 2 dose (RP2D)/optimal dose of LOXO-435: Safety, number of participants with dose-limiting toxicities (DLTs)	Jun 2025	Jun 2025
Nectin-4 ADC 1	NCT06238479	Metastatic Solid Tumor	A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors	1	280	Phase 1a: To determine the recommended dose of LY4101174: Number of participants with dose-limiting toxicities (DLTs)	Aug 2026	Mar 2027

[1] Also lists Merck Sharp & Dohme LLC

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2024

Select Trials – Early Phase Pain

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
SSTR4 Agonist	NCT06074562	Diabetic Peripheral Neuropathy	A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain	2	410	Mean Change from Baseline for Average Pain Intensity Numeric Rating Scale (API-NRS)	Jan 2025	Jan 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 16, 2024


Lilly